Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 12/20 | 0.56 |
| ▸ | PRCP | P42785 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7681572 | 1.00 | FKBP1A (0.56) | FKBP1APRCPACEACE2ALDH1A1 | |
| SCHEMBL6787501 | 0.83 | FKBP1A (0.55) | FKBP1APRCPPREP | |
| SCHEMBL6787511 | 0.83 | FKBP1A (0.55) | FKBP1APRCPPREP | |
| SCHEMBL6787506 | 0.83 | FKBP1A (0.55) | FKBP1APRCPPREP | |
| SCHEMBL6863773 | 0.81 | FKBP1A (0.53) | FKBP1APRCPACEACE2 | |
| SCHEMBL6787667 | 0.80 | FKBP1A (0.59) | FKBP1AACEALDH1A1CYP3A4TSHR | |
| SCHEMBL6787654 | 0.80 | FKBP1A (0.59) | FKBP1AACEALDH1A1CYP3A4TSHR | |
| SCHEMBL6783150 | 0.79 | FKBP1A (0.60) | FKBP1AACEALDH1A1CYP3A4TSHR | |
| SCHEMBL6783143 | 0.79 | FKBP1A (0.60) | FKBP1AACEALDH1A1CYP3A4TSHR | |
| SCHEMBL6783144 | 0.79 | FKBP1A (0.60) | FKBP1AACEALDH1A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | FKBP1A 599/4885PRCP 447/4885ACE 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.